CMTTdb

An integrated database for cancer molecular targeted thearpies

Entry Detail


General information
Database:DB00506
Objective:A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFNalpha) in progression free survival (primary end point) as firstline treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported.
Authors:Motzer RJ, et al
Title:Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Journal:J Clin Oncol.
Year:2009
PMID:19487381
Trial Design
Clinical Trial Id:NCT00083889
Agent:sunitinib
Target:FL cytokine receptor
Mast/stem cell growth factor receptor
Vascular endothelial growth factor receptor 2
Plateletderived growth factor receptor
Cancer Type:renal cell carcinoma
Cancer Subtype:advanced renal cell carcinoma
Therapy Type:mono
Therapeutic Combination Type:NA
Therapeutic Combination Content:NA
Study Type:an international, multicenter, randomized, phase III trial
Key Patients Feature:The study population comprised patients 18years of age who had treatmentna ve metastatic RCC with a clear cell component. Additional eligibility criteria were previouslyreported.
Biomarker:NA
Biomark Analysis:NA
Control Group Info:A: sunitinib B: IFNalpha
Treatment Info:pts were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFNalpha 9 MU subcutaneously thrice weekly.
Primary End Point:progression free survival.
Secondary End Point:objective response rate, overall survival, patientreported outcomes, and safety.
Patients Number:715
Trial Results
DLT_MTD:Most treatmentrelated adverse events occurred more frequentlyin the sunitinib group than in the IFN group (Table 1). In bothgroups, the proportion of grade 3 or 4 adverse events and laboratoryabnormalities remained relatively low and consistent with longtermtreatment compared with those reported in the interim analysis
Objective Response Rate:Median overall survival was greater in the sunitinib group than in the IFN group (26.4 v 21.8 months, respectively; hazard ratio [HR] 0.821; 95% CI, 0.673 to 1.001; P .051) per the primary analysis ofunstratified logrank test (P .013 per unstratified Wilcoxon test). By stratified logrank test, the HRwas 0.818 (95% CI, 0.669 to 0.999; P .049). Within the IFN group, 33% of patients receivedsunitinib, and 32% received other vascular endothelial growth factor-signaling inhibitors after discontinuationfrom the trial.
Disease Control Rate:87% in sunitinib and 66% in IFN
Median Time to Progression:NA
Median PFS A vs. C:11 months for sunitinib compared with 5 months for IFN (P .001).
Median OS A vs. C:Median overall survival was greater in the sunitinib group than in the IFN group (26.4 v 21.8 months, respectively; hazard ratio [HR] 0.821; 95% CI, 0.673 to 1.001; P .051) per the primary analysis of unstratified logrank test (P .013 per unstratified Wilcoxon test).
Adverse Event(agent arm):The most commonly reported sunitinibrelated grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and handfoot syndrome (9%).
Conclusions:Sunitinib demonstrates longer overall survival compared with IFNalpha plus improvement in response and progression free survival in the firstline treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.